453 related articles for article (PubMed ID: 19304584)
21. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration.
Chung SE; Kang SW; Lee JH; Kim YT
Ophthalmology; 2011 May; 118(5):840-5. PubMed ID: 21211846
[TBL] [Abstract][Full Text] [Related]
22. Cross-sectional and en face optical coherence tomographic features of polypoidal choroidal vasculopathy.
Saito M; Iida T; Nagayama D
Retina; 2008 Mar; 28(3):459-64. PubMed ID: 18327139
[TBL] [Abstract][Full Text] [Related]
23. Peripheral polypoidal choroidal vasculopathy as a cause of peripheral exudative hemorrhagic chorioretinopathy: a report of 10 eyes.
Goldman DR; Freund KB; McCannel CA; Sarraf D
Retina; 2013 Jan; 33(1):48-55. PubMed ID: 22836900
[TBL] [Abstract][Full Text] [Related]
24. Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with photodynamic therapy.
Byeon SH; Lew YJ; Lee SC; Kwon OW
Acta Ophthalmol; 2010 Sep; 88(6):660-8. PubMed ID: 19563374
[TBL] [Abstract][Full Text] [Related]
25. Differentiating Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy Using OCT B-Scan.
Kokame GT; Omizo JN; Kokame KA; Yamane ML
Ophthalmol Retina; 2021 Oct; 5(10):954-961. PubMed ID: 34022443
[TBL] [Abstract][Full Text] [Related]
26. Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Kokame GT; deCarlo TE; Kaneko KN; Omizo JN; Lian R
Ophthalmol Retina; 2019 Sep; 3(9):744-752. PubMed ID: 31511169
[TBL] [Abstract][Full Text] [Related]
27. EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study.
Tan CS; Ngo WK; Lim LW; Tan NW; Lim TH;
Graefes Arch Clin Exp Ophthalmol; 2016 Oct; 254(10):1923-1930. PubMed ID: 27142805
[TBL] [Abstract][Full Text] [Related]
28. Angiographic findings in patients with exudative age-related macular degeneration.
Bermig J; Tylla H; Jochmann C; Nestler A; Wolf S
Graefes Arch Clin Exp Ophthalmol; 2002 Mar; 240(3):169-75. PubMed ID: 11935273
[TBL] [Abstract][Full Text] [Related]
29. Changes in fundus autofluorescence after treatments for polypoidal choroidal vasculopathy.
Yamagishi T; Koizumi H; Yamazaki T; Kinoshita S
Br J Ophthalmol; 2014 Jun; 98(6):780-4. PubMed ID: 24515988
[TBL] [Abstract][Full Text] [Related]
30. Peripheral exudative hemorrhagic chorioretinopathy: polypoidal choroidal vasculopathy and hemodynamic modifications.
Mantel I; Schalenbourg A; Zografos L
Am J Ophthalmol; 2012 May; 153(5):910-922.e2. PubMed ID: 22310077
[TBL] [Abstract][Full Text] [Related]
31. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability.
Koizumi H; Yamagishi T; Yamazaki T; Kinoshita S
Am J Ophthalmol; 2013 Feb; 155(2):305-313.e1. PubMed ID: 23022162
[TBL] [Abstract][Full Text] [Related]
32. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.
Otani A; Sasahara M; Yodoi Y; Aikawa H; Tamura H; Tsujikawa A; Yoshimura N
Am J Ophthalmol; 2007 Jul; 144(1):7-14. PubMed ID: 17467649
[TBL] [Abstract][Full Text] [Related]
33. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Song MH; Ryu HW; Roh YJ
Ophthalmologica; 2011; 226(3):119-26. PubMed ID: 21757883
[TBL] [Abstract][Full Text] [Related]
34. Retinal pigment epithelial tear in polypoidal choroidal vasculopathy.
Tsujikawa A; Hirami Y; Nakanishi H; Ojima Y; Aikawa H; Tamura H; Otani A; Yoshimura N
Retina; 2007 Sep; 27(7):832-8. PubMed ID: 17891005
[TBL] [Abstract][Full Text] [Related]
35. Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of polyps resembling grape clusters.
Lee WK; Kim KS; Kim W; Lee SB; Jeon S
Am J Ophthalmol; 2012 Aug; 154(2):355-365.e1. PubMed ID: 22541658
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.
Saito M; Iida T; Kano M
Retina; 2011 Sep; 31(8):1589-97. PubMed ID: 21654347
[TBL] [Abstract][Full Text] [Related]
37. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Kim HS; Jang YS; Han JI; Lew YJ; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
[TBL] [Abstract][Full Text] [Related]
38. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor.
Lee MY; Lee WK; Baek J; Kwon OW; Lee JH
Am J Ophthalmol; 2013 Aug; 156(2):343-8. PubMed ID: 23664208
[TBL] [Abstract][Full Text] [Related]
39. Pulsatile blood flow in the polypoidal choroidal vasculopathy.
Okubo A; Ito M; Sameshima M; Uemura A; Sakamoto T
Ophthalmology; 2005 Aug; 112(8):1436-41. PubMed ID: 15996735
[TBL] [Abstract][Full Text] [Related]
40. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment.
Koh AH; ; Chen LJ; Chen SJ; Chen Y; Giridhar A; Iida T; Kim H; Yuk Yau Lai T; Lee WK; Li X; Han Lim T; Ruamviboonsuk P; Sharma T; Tang S; Yuzawa M
Retina; 2013 Apr; 33(4):686-716. PubMed ID: 23455233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
